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Background: In autoimmune disorders, the underlying pathogenic mechanism is the formation of antigen-antibody
complexes which trigger an inflammatory response by inducing the infiltration of neutrophils. Epithelial cell-derived
neutrophil-activating peptide-78 (ENA-78) is a chemokine that recruits and activates neutrophils, thus it could play a
pathogenic role in inflammation and autoimmune disorders. Some autistic children have elevated levels of brain
specific auto-antibodies. We are the first to evaluate serum expression of ENA-78 and its relation to antineuronal
auto-antibodies in autistic children.
Methods: Serum ENA-78 and antineuronal auto-antibodies were measured by ELISA test in 62 autistic children aged
between 4–11 years and 62 health-matched controls.
Results: Serum levels of ENA-78 were significantly higher in autistic children than healthy controls (P < 0.001). Increased
serum levels of ENA-78 have been found in 69.35% of autistic patients. In addition, autistic children had significantly
higher percent positivity of serum antineuronal auto-antibodies (64.5%) than healthy controls (6.45%), P < 0.001. There
was a significant positive association between the positivity of serum antineuronal auto-antibodies and the elevated
levels of serum ENA-78 (P < 0.001) in autistic children.
Conclusions: Serum levels of ENA-78 were elevated in autistic children and they were significantly associated with the
increased levels of serum antineuronal auto-antibodies. However, these data should be treated with caution until
further research is conducted to determine the pathogenic role of ENA-78 in autism and its relation to brain specific
auto-antibodies that have been found in some autistic children. The possible therapeutic role of ENA-78 antagonist in
autistic children should be also studied.
Keywords: Autism, Autoimmunity, Chemokines, Epithelial cell-derived neutrophil-activating peptide-78, Antineuronal
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Chemokines are a large group of chemotactic cytokines.
They have been divided into four groups, designated CXC,
CC, C and CX3C, depending on the spacing of conserved
cytokines (where X is an amino acid). The CXC chemo-
kines mainly target neutrophils and lymphocytes whereas* Correspondence: gehan.mostafa2000@yahoo.com
1Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo,
Egypt
2Autism Research and Treatment Center, AL-Amodi Autism Research Chair,
Department of Physiology, Faculty of Medicine, King Saud University, Riyadh,
Saudi Arabia
© 2015 Mostafa and Al-Ayadhi; licensee BioMe
Creative Commons Attribution License (http://c
and reproduction in any medium, provided t
Dedication waiver (http://creativecommons.o
unless otherwise stated.the CC chemokines target a variety of cell types, including
macrophages, eosinophils, basophils and dendritic cells [1].
Recruitment of inflammatory cells plays the key pathogenic
role in all inflammatory diseases and autoimmune disor-
ders. Not only are chemokines involved in recruitment of
these cells, but they also play a role in their activation and
differentiation [2]. Inflammation is characterized by the
local tissue expression of chemokines [3-6]. Chemokines
and their receptors are important potential therapeutic tar-
gets in many inflammatory and autoimmune disordersd Central. This is an Open Access article distributed under the terms of the
reativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution,
he original work is properly credited. The Creative Commons Public Domain
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tion during inflammation [2].
Epithelial cell-derived neutrophil-activating peptide-78
(ENA-78/CXCL5), is a CXC chemokine that attracts
neutrophils [7]. In the healthy tissue, epithelial cells are
the primary source of this chemokine. On the other
hand, in the inflamed tissue, inflammatory cells that in-
filtrate the submucosa are the major cellular source of
this chemokine [8]. Neutrophils belong to the body’s first
line of cellular defense and respond quickly to tissue in-
jury and invading microorganisms [9]. In autoimmune
disorders, the underlying pathogenic mechanism is the
formation of antigen-antibody complexes, so-called im-
mune complexes (ICs), which trigger an inflammatory
response by inducing the infiltration of neutrophils [10].
The presence of auto-antibodies to neural tissues/anti-
gens in autism [11-17] and the increase in the frequency
of autoimmune disorders among autistic families [18-21]
suggest that autoimmunity may play an important role
in the pathogenesis of autism [11]. Chemokines and
their receptors have been implicated as functional medi-
ators of immunopathology of autoimmune neuroinflam-
matory diseases [22,23].
This study was the first to evaluate serum expression
of ENA-78 and its relation to antineuronal brain specific
auto-antibodies in autistic children.
Methods
Study population
This cross-sectional study was conducted on 62 autistic
children. They were recruited from the Pediatric
Neuropsychiatric Clinic, Faculty of Medicine of Ain Shams
University, Cairo, Egypt, during their follow up visits.
Patients were fulfilling the criteria of the diagnosis of autism
according to the 4th edition of the Diagnostic and Statistical
Manual of Mental Disorders [24]. The autistic group com-
prised 48 males and 14 females. Their ages ranged between
4 and 11 years (mean ± SD = 6.9 ± 1.9 years). Patients who
had associated neurological diseases (such as cerebral palsy
and tuberous sclerosis), metabolic disorders (eg.
Phenylketonuria), allergic manifestations or concomitant in-
fection were excluded form the study.
The control group comprised 62 age- and sex- matched
apparently healthy children. They included 47 males and
15 females. They were recruited from the Outpatients
Clinic, Children’s Hospital, Faculty of Medicine, Ain
Shams University. They were the sibs of the children at-
tending this clinic because of a minor illness (e.g. common
cold, tonsillitis and acute bronchitis). The control children
were not related to the children with autism, and demon-
strated no clinical findings suggestive of infections, allergic
manifestations and immunological or neuropsychiatric
disorders. Their ages ranged between 5 and 12 years
(mean ± SD= 7.08 ± 1.78 years).The local Ethical Committee of the Faculty of
Medicine, Ain Shams University, Cairo, Egypt approved
this study. In addition, an informed written consent of
participation in the study and its publication was signed
by the parents or the legal guardians of the studied
subjects.
Study measurements
Clinical evaluation of autistic patients
This was based on clinical history taking from care-
givers, clinical examination and neuropsychiatric assess-
ment. In addition, the degree of the disease severity was
assessed by using the Childhood Autism Rating Scale
(CARS) [25] which rates the child on a scale from one
to four in each of fifteen areas (relating to people; emo-
tional response; imitation; body use; object use; listening
response; fear or nervousness; verbal communication;
non-verbal communication; activity level; level and
consistency of intellectual response; adaptation to
change; visual response; taste, smell and touch response
and general impressions).
Assessment of cognitive function (memory, attention,
language, concept formation, problem solving, executive
and visuospatial functions) with age-appropriate, trans-
lated and validated psychometric instruments that were
administered by well-trained psychologists using a set of
Arabic norms [26] for a translated Wechsler Intelligence
Scale for Children, 3rd edition (WISC-III) [27]. This
scale is the most commonly used test to assess cognitive
function in the children. Three global measures were ex-
amined in the present study. The verbal intelligence
quotient (IQ) is derived from different subtests including
information, similarities, arithmetic, comprehension, vo-
cabulary and digit span. The performance IQ is derived
from different subtests including picture completion,
block design, picture arrangement, object assembly and
digit symbol. The full-scale IQ is the sum of the verbal
and performance IQ. The individual subtests may be
particularly useful because each depends on a variety of
capabilities and dysfunction of any one could result in a
low score on one of the global measures. Cognitive dys-
function is diagnosed when the difference between ver-
bal and performance IQ is more than 15 and/or the
result of one or more of the individual subtests is below
7 and/or the full scale IQ is below 70.
Assessment of serum ENA-78 levels
The assay employs the quantitative sandwich enzyme
immunoassay technique (R and D systems Inc., 614
Mclinley Place NE Minenopolis MN 55413, USA).
Serum samples were stored at −70°C until assay of
ENA-78. A monoclonal antibody specific for ENA-78
has been pre-coated onto a microplate. Standards and
samples are pipetted into the wells and any ENA-78
Table 1 Demographic and laboratory data of children





(n = 62) (n = 62)
Age (in years): Range 4-11 5-12
Mean ± SD 6.9 ± 1.9 7.08 ± 1.78
Sex: (Male/Female) 48/14 47/15
Intelligence quotient: Above 70 45.16% 100%
50-69 32.26%
35-49 22.58%




Serum ENA-78: Range 110.25-1295.89 60-382.69
(pg/ml) Median (IQR) 186.26 (105) 112.5 (115)
Positivity of antineuronal antibodies 64.5% 6.45%
CARS, Childhood Autism Rating Scale; ENA-78, epithelial cell-derived
neutrophil-activating peptide-78; IQ,R, interquartile ranges.
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washing away any unbound substances, an enzyme-
linked polyclonal antibody specific for ENA-78 is added
to the wells. Following a wash to remove any unbound
antibody-enzyme reagent, a substrate solution is added
to the wells and color develops in proportion to the
amount of ENA-78 bound in the initial step. The color
development is stopped and the intensity of the color is
measured by ELISA recorder. To increase accuracy, all
samples were analysed twice in two independent experi-
ments to assess the interassay variations and to ensure
reproducibility of the observed results. There were no
discordant data between the results (P > 0.05). No sig-
nificant cross-reactivity or interference was observed.
Assessment of serum antineuronal auto-antibodies
This assay employs the indirect immunofluorescence tech-
nique (Euroimmun Labaretorium Fur Eperimentelle
Immunologie, Germany). Two milliliters of venous blood
were collected and transferred into a dry clean tube and
left to clot at room temperature. Then, centrifugation was
done at 3000 rpm for 5 min. Prompt separation of serum
was done. Forzen sections of primate cerebellum covering
the reaction area of a biochip slide were incubated with a
diluted serum sample. If the sample was positive, specific
antibodies of classes IgA, IgG and IgM attached to the
neuronal antigens. In a second step the attached anti-
bodies were stained with fluorescence-labeled anti-human
antibodies and made visible with the fluorescence micro-
scope. To increase accuracy, all samples were analyzed
twice in two independent experiments to assess inter-
assay variations and to ensure reproducibility of the ob-
served results (P > 0.05). No significant cross-reactivity or
interference was observed.
Statistical analysis
The results were analyzed by using the commercially
available software package (Statview, Abacus concepts,
inc., Berkley, CA, USA). The parametric data were pre-
sented as mean and standard deviation (SD). In addition,
non-parametric data were presented as median and
interquartile range (IQR) which is between the 25th and
75th percentiles. Student’s t-test was used for comparison
of parametric data, while Mann–Whitney test was used
for comparison between non-parametric data. Chi-
square test was used for comparison between qualita-
tive variables of the studied groups. Spearman’s rho
correlation coefficient “r” was used to determine the
relationship between different variables. For all tests, a
probability (P) of less than 0.05 was considered signifi-
cant. The patient was considered to have an elevated
serum ENA-78 level if it was above 158.85 pg/ml which
was the chosen highest cut-off value (the 95th or the
control values as data were non-parametric).Results
All studied patients had classic-onset autism. None of
the autistic patients had regressive autism, associated
neurological diseases (such as cerebral palsy and tuber-
ous sclerosis), metabolic disorders (e.g., Phenylketonuria),
allergic manifestations or concomitant infections. The
degree of the disease severity was assessed by using
CARS and according to this scale, children who have
scored 30–36 have mild to moderate autism (n = 28),
while those with scores ranging between 37 and 60
points have a severe degree of autism (n = 34). In
addition, 34 autistic children had subnormal intellectual
function (intelligence quotient below 70); 20 had mild
mental retardation (intelligence quotient = 50–69), and
14 had moderate mental retardation (intelligence quo-
tient = 35–49), Table 1. Of the 34 autistic children with
subnormal intellectual function, 26 had severe autism
and 8 had mild to moderate autism. None of the healthy
control children had a neurocognitive disorder.Serum levels of ENA-78 in autistic children and healthy
control children
Serum levels of ENA-78 were significantly higher in autistic
children [median (IQR) = 186.26 (105) pg/ml] than healthy
control children [median (IQR) = 112.5 (115) pg/ml],
P < 0.001 (Figure 1). Forty three autistic children
(69.35%) had increased serum levels of ENA-78.
There were no significant correlations between serum
levels of ENA-78 and the age of autistic children, results
of CARS and values of intelligence quotient (P > 0.05).
Figure 1 Serum levels of ENA-78 in autistic patients and healthy controls. Horizontal bars indicate the median values. ENA-78, epithelial
cell-derived neutrophil-activating peptide-78. The boxes enclose the interquartile ranges (IQR) which are between the 25th and 75th percentiles.
The horizontal line inside the box represents the median and the whiskers represent the non-outlier (between 1.5 and 3 IQR above the 75th
percentile) or extreme (more than 3 IQR above the 75th percentile) maximum and minimum values of serum ENA-78 levels. The small open and
black squares represent the outlier (between 1.5 and 3 IQR) or extreme values (more than 3 IQR), respectively of serum ENA-78 levels in
autistic children.
Table 2 The frequency of autistic patients with increased









(n = 40) (n = 22)
Positive antineuronal
antibodies (n = 43)
36 (90%) 7 (31.8%) 22.6
Negative antineuronal
antibodies (n = 19)
4 (10%) 15 (68.2%) (<0.001)
ENA-78, epithelial cell-derived neutrophil-activating peptide-78.
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in autistic children and healthy control children
Forty autistic children (64.5%) had positive results of
serum antineuronal auto-antibodies. Autistic children
had significantly higher percent positivity of serum anti-
neuronal antibodies than healthy controls (6.45%; 4/62),
P < 0.001.
The association between increased serum levels
of ENA-78 and the positive results of serum antineuronal
auto-antibodies
Autistic patients with increased serum levels of ENA-78
had significantly higher frequency of positive results of
serum antineuronal auto-antibodies (90%) than patients
with normal serum levels of ENA-78 (31.8%), P < 0.001
(Table 2). Thus, there was a significant positive associ-
ation between the elevated levels of serum ENA-78 and
the positivity of serum antineuronal auto-antibodies in
autistic children.
Discussion
Chemokines are a large group of chemotactic cytokines
that play an important pathogenic role in inflammatory
diseases and autoimmune disorders by enhancement ofleukocyte recruitment and activation at inflammatory
sites [3-6]. ENA-78 is a CXC chemokine that attracts
neutrophils during inflammation [7].
In this work, serum levels of ENA-78 were significantly
higher in autistic children than healthy control children
(P < 0.001). In addition, 69.35% of autistic children had in-
creased serum levels of ENA-78. This study was the first
to investigate serum levels of ENA-78 in autistic children.
ENA-78 is an inflammatory C-X-C chemokine that is
encoded by the CXCL5 gene [28]. Its levels are elevated in
myriad inflammatory conditions [29-32].
Mostafa and AL-Ayadhi Behavioral and Brain Functions  (2015) 11:11 Page 5 of 7ENA-78 is an α chemokine which is produced concomi-
tantly with IL-8 and melanoma growth stimulating activity
[7]. The main stimuli for secretion of chemokines, including
ENA-78, are the early signals elicited during innate immune
response such as bacterial products, viral infection and pro-
inflammatory cytokines. Notably, chemokines are induced
rapidly, within one hour, by these triggers and provide an
important link between early innate immune responses and
adaptive immunity [7,8]. ENA-78 can act in concert with IL-
8 to stimulate neutrophil directed chemotaxis, neutrophil
activation via increasing the intracellular level of free calcium
and elastase release and it can also induce neutrophil proad-
hesive activity [33,34]. Neutrophils contribute to the devel-
opment of inflammation as they play a role in tissue
remodeling. This ability stems in part from the angiogenic
property of a subgroup of neutorphil activating CXC chemo-
kines including ENA-78. In the inflamed tissue, infiltrating
inflammatory cells are the major cellular source of this che-
mokine [8]. Immunocytochemistry detected ENA-78 in eo-
sinophils and the peptide was localized in the specific
granules. This may suggest that, through expression of
ENA-78, eosinophils can recruit and activate CXC receptor
2-bearing cells such as neutrophils at sites of inflammation.
Eosinophils may also promote connective tissue remodeling
through release of this peptide [7,35].
The transport or synthesis of cytokines in the brain may
contribute to neuroinflammation and possible neurotrans-
mitter imbalances in autism [11]. Immunocytochemical
studies showed marked activation of microglia and astro-
glia, and cytokine profiling indicated that macrophage
chemoattractant protein-1 and tumor growth factor-beta1,
derived from neuroglia, were the most prevalent cytokines
in brain tissues. CSF showed a unique pro-inflammatory
profile of cytokines, including a marked increase in MCP-1
[36]. Elevated plasma MCP-1, RANTES and eotaxin in
some autistic children and their association with more im-
paired behaviors may have etiological significance [37].
Serum levels of Th2 chemoattractants CCR4 ligands che-
mokines, macrophage-derived chemokine and thymus and
activation- regulated chemokine, were reported to be ele-
vated in autistic children [38]. One study reported elevated
serum levels of osteopontin, which is a potent chemo-
attractive pro-inflammatory cytokine, produced by immune
cells in autistic children [39]. Another study reported re-
duced levels of progranulin, which is an anti-inflammatory
neurotrophic factor, potently inhibit neutrophilic inflamma-
tion in autistic children [40]. Chemokines and their recep-
tors might provide unique targets for future therapies in
autism [37].
In the current study, 64.5% of autistic children had posi-
tive results of serum antineuronal auto-antibodies. A recent
study reported positivity of serum antineuronal auto-
antibodies in 62.5% of a group of 80 Saudian children with
autism [18]. In some autistic children there is an imbalanceof T-helper (Th)1/Th2 subsets toward Th2, which are
responsible for allergic response and production of anti-
bodies [11]. It is postulated that antineuronal auto-
antibodies produce diffuse brain abnormalities and their
major autoantigens are unidentified. Antineuronal auto-
antibodies bind to the surface membranes of neurons
causing direct cytotoxic neuronal injury and affecting the
neuronal function [41]. Antineuronal auto-antibodies may
play an etiopathogenic role in some autoimmune neuro-
logical disorders such as cognitive dysfunction found in
patients neuropsychiatric systemic lupus erythematosus
and multiple sclerosis [42-44].
Autism may be a disorder of the immune system that
occur in a very early phase of embryonic development.
Genetic predisposition and environmental predisposition
could trigger a deranged immune response which, in
turn, results in damage to specific areas of CNS [45].
The pathological role of autoantibodies in development
of CNS disorders is a new idea with growing interest
among neuroscientists. The involvement of autoimmune
response in the pathogenesis of autism has been sug-
gested by the presence of multiple brain-specific auto-
antibodies in children with autism and in their mothers.
The presence of autoantibodies against human neuronal
progenitor cells suggest an impaired tolerance to neural
antigens in autism. These autoantibodies may affect
postnatal neuronal plasticity particularly after impair-
ment of blood–brain barrier [46]. The evidence of a
pathomorphic role for 37, 39 and 73 kDa anti-brain anti-
bodies in autism has been recently reported [47].
Immuno-inflammatory pathways and mitochondrial dys-
function play significant interactive roles in driving the
early developmental etiology and course of autism [48].
Activation of mast cells in autistic children is accompan-
ied by mitochondrial fission and translocation to the cell
surface from where they secrete at least ATP and DNA
outside the cell without cell damage. These extracellular
mitochondrial components are misconstrued by the
body as “innate pathogens” leading to powerful auto-
crine and paracrine auto-immune/auto-inflammatory re-
sponses, a condition that could involve “focal brain
allergy/encephalitits” [49].
Despite of the fact that the origin of autoimmunity in
autism is unknown, immune related genes on major
histocompatibility complex, which have been associated
with some autoimmune diseases, may play a central role
in the development of autoimmunity in autism such as
increased frequency of C4B null alleles in class III re-
gion. This results in low production of C4B protein lead-
ing to repeated infections which may play an important
role in the development of autoimmune reaction to neu-
rons [20,50] through antigenic mimicry, with a subse-
quent release of neuronal antigens. These neuronal
antigens may result in the induction of autoimmune
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cells in genetically susceptible individuals. The
formed antibodies may cross the blood brain barrier
and combine with brain tissue antigens forming im-
mune complexes, thus further damaging the neuro-
logical tissue [11,51].
The current study revealed that autistic patients with in-
creased serum levels of ENA-78 had significantly higher
frequency of positive results of serum antineuronal auto-
antibodies (90%) than patients with normal serum levels
of ENA-78 (31.8%), P < 0.001. Thus, there was a significant
positive association between the elevated levels of serum
ENA-78 and the positivity of serum antineuronal auto-
antibodies in autistic children. This is the first study that
investigated the relationship between chemokines and
autoimmunity in autism.
Chemokines and their receptors have been implicated as
functional mediators of immunopathology of autoimmune
neuroinflammatory diseases [22,23,38]. ENA-78 is a CXC
chemokine that attracts neutrophils during inflammation
[7]. Neutrophils have a pathogenic role in autoimmunity
[52]. In autoimmune disorders, the underlying pathogenic
mechanism is the formation of antigen-antibody com-
plexes, so-called immune complexes (ICs), which trigger an
inflammatory response by inducing the infiltration of neu-
trophils [10]. The subsequent stimulation of neutrophils by
C3b-opsonized ICs results in the generation of reactive
oxygen species (ROS) and the release of intracellularly
stored proteases leading to tissue damage and inflammation
[53]. It is therefore important to identify the mechanisms
that control the activation of infiltrating neutrophils [54].
Chemokines and their receptors are important poten-
tial therapeutic targets in many inflammatory and auto-
immune disorders because of their central role in cell
recruitment and activation during inflammation.
Targeting the chemokine system is generally done by af-
fecting chemokine receptor binding which can be done
in three ways: by using blocking antibodies, by modifica-
tion of chemokines and therefore antagonizing chemo-
kine receptors and by using small molecule chemokine
receptor antagonists [2,55]. The possible therapeutic role
of ENA-78 antagonism in autistic children should be
studied.
This study revealed that the increase of ENA-78 levels
may promote the induction of autoimmunity through
stimulation of neutrophil activation. We could not trace
data in the literature regarding the neutrophil function
in autistic patients, so studies should be conducted to
investigate neutrophil function in these patients. As this
study is the first that investigated the relationship be-
tween chemokines and autoimmunity in autism, we rec-
ommend future studies that relate the altered levels of
different chemokines and the production of many types
of brain specific auto-antibodies in autistic children.Conclusions
Serum levels of ENA-78 were elevated in autistic chil-
dren and they were significantly associated with the in-
creased levels of serum antineuronal auto-antibodies.
However, these data should be treated with caution until
further research is conducted to determine the patho-
genic role of ENA-78 in autism and its relation to brain
specific auto-antibodies that found in some autistic chil-
dren. The possible therapeutic role of ENA-78 antagon-
ism in autistic children should be also studied.
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